#ESMO20: Trodelvy data show that Gilead's $21B buyout may have been worth the big premium
Gilead CEO Dan O’Day has been on a shopping spree. And while some analysts gawked at the biotech’s recent $21 billion Immunomedics buyout, new data released at virtual ESMO 2020 suggest the acquisition may have been worth the hefty price.
The deal, announced last weekend, will give California-based Gilead $GILD Trodelvy, which was recently approved for metastatic triple-negative breast cancer (mTNBC).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,000+ biopharma pros reading Endpoints daily — and it's free.